Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
RMD Open|December 19, 2023
Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French health insurance database (SNDS)Laura Pina Vegas, Laetitia Penso, Emilie Sbidian, et al.
RMD Open|August 8, 2024
Impact of initiation of targeted therapy on the use of psoriatic arthritis-related treatments and healthcare consumption: a cohort study of 9793 patients from the French health insurance database (SNDS)Laura Pina Vegas, Siham Iggui, Emilie Sbidian, et al.
JAMA Dermatology|March 23, 2022
Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance DatabaseLaura Pina Vegas, Laetitia Penso, Pascal Claudepierre, et al.
Rheumatology (Oxford, England)|September 10, 2020
Epidemiologic study of patients with psoriatic arthritis in a real-world analysis: a cohort study of the French health insurance databaseLaura Pina Vegas, Emilie Sbidian, Laetitia Penso, et al.
Joint Bone Spine|September 16, 2022
Prevalence, mortality, and treatment of patients with rheumatoid arthritis: A cohort study of the French National Health Data System, 2010-2019Laura Pina Vegas, Jérôme Drouin, Rosemary Dray-Spira, et al.
RMD Open|January 19, 2024
Pregnancy outcomes in women with rheumatoid arthritis: an 11-year French nationwide studyLaura Pina Vegas, Jérôme Drouin, Alain Weill, et al.
RMD Open|January 4, 2023
Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS)Laura Pina Vegas, Léa Hoisnard, Léa Bastard, et al.
RMD Open|March 14, 2024
Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (SNDS)Léa Bastard, Pascal Claudepierre, Laetitia Penso, et al.
Annals of the Rheumatic Diseases|October 5, 2022
Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort studyLea Hoisnard, Laura Pina Vegas, Rosemay Dray-Spira, et al.
Rheumatology (Oxford, England)|July 10, 2021
Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort studyLaura Pina Vegas, Philippe Le Corvoisier, Laetitia Penso, et al.
Pageof 3